SPS
CTMX icon

Susquehanna Portfolio Strategies’s CytomX Therapeutics CTMX Stock Holding History

Susquehanna Portfolio Strategies’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$226K Hold
48,012
– – ﹤0.01% 891
2025
Q4 		$205K Hold
48,012
– – ﹤0.01% 947
2025
Q3 		$153K Sell
48,012
-51,398
-52% -$116K ﹤0.01% 996
2025
Q2 		$226K Buy
+99,410
New +$160K ﹤0.01% 784
2024
Q1 		– Sell
-31,869
Closed -$49.4K – 824
2023
Q4 		$49.4K Buy
+31,869
New +$41.9K ﹤0.01% 987

Other funds holding CTMX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Susquehanna Portfolio Strategies's CTMX Position: Q1 2026 in Review

Susquehanna Portfolio Strategies held its CytomX Therapeutics (CTMX) position steady in Q1 2026 at 48,012 shares worth $226K. The position accounts for ﹤0.01% of the portfolio, ranked #891.

Susquehanna Portfolio Strategies first reported a position in CTMX in Q4 2023 and has held it in 5 quarters since. The position peaked at $226K in Q2 2025. 179 funds tracked by Wall St. Rank hold CTMX as of Q1 2026.

  • Susquehanna Portfolio Strategies held 48,012 shares of CytomX Therapeutics worth $226K as of Q1 2026.
  • Susquehanna Portfolio Strategies left its CytomX Therapeutics share count unchanged in Q1 2026.
  • CytomX Therapeutics made up ﹤0.01% of Susquehanna Portfolio Strategies's portfolio in Q1 2026, its #891 holding.
  • Susquehanna Portfolio Strategies first reported a position in CytomX Therapeutics in Q4 2023 and has held it in 5 quarters since.
  • Susquehanna Portfolio Strategies's CytomX Therapeutics position peaked at $226K in Q2 2025.
  • 179 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q1 2026.

Based on Susquehanna Portfolio Strategies's 13F filing for Q1 2026, filed 15 May 2026.